RudaCure has completed the expansion of its Seoul office, which began on July 18th.
The Seoul office, spanning a total of 145 pyeong (approximately 480 m²), has been relocated with the Clinical Team at its core along with the in vitro analysis team. As a result, the existing headquarters in Songdo will focus on in vivo efficacy testing and internal pipeline research, while the Seoul office will conduct MoA analysis alongside FLIPR services.
With the expansion of the business premises, the company will reorganize its research structure and strengthen its internal capabilities by reinforcing the research team. Through organizational restructuring, the plan is to accelerate both domestic and overseas clinical trials for RCI001 while simultaneously strengthening new pipelines.
The Seoul office is located at Ace Hi-End 3rd Building, Suite 1001, Gasan Digital Complex.
